Skip Navigation


International Immunology Advance Access originally published online on August 14, 2009
International Immunology 2009 21(10):1135-1144; doi:10.1093/intimm/dxp077
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
21/10/1135    most recent
dxp077v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Ju, S.
Right arrow Articles by Zhang, X.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ju, S.
Right arrow Articles by Zhang, X.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Japanese Society for Immunology. 2009. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

A novel approach to induce human DCs from monocytes by triggering 4-1BBL reverse signaling

Songwen Ju1,2,*, Songguang Ju1,*, Yan Ge1, Hongxia Qiu3, Binfeng Lu4, Yuhua Qiu1, Jingxiang Fu1, Gaoqin Liu1, Qin Wang1, Yumin Hu1, Yongqian Shu2 and Xueguang Zhang1

1 Biotechnology Institute, Soochow University, Suzhou, Jiangsu Province, People's Republic of China
2 Cancer Biotherapy Center
3 Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province, People's Republic of China
4 Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA

Correspondence to: Songguang Ju; E-mail: songguang_ju{at}hotmail.com / Xueguang Zhang; E-mail: xueguangzh{at}yahoo.com.cn

Dendritic cells (DCs) are responsible for the initiation of immune responses. Our study demonstrates a new pathway for generating a large quantity of stimulatory monocyte-derived DCs (Mo-DCs) from human monocytes using anti-4-1BB ligand (4-1BBL) mAb to trigger reverse signaling. The anti-4-1BBL-driven Mo-DCs (DCs{alpha}-4-1BBL) not only express higher levels of CD86, CD83 and HLA-DR, when compared with the Mo-DCs matured by tumor necrosis factor {alpha}, but also exhibit a unique phenotype that expresses lower levels of PD-L1. High levels of GM-CSF, M-CSF and Flt3 ligand (FL) were found in the anti-4-1BBL-differentiation culture. Neutralizing M-CSF, GM-CSF and FL inhibited Mo-DC proliferation stimulated by anti-4-1BBL mAb, suggesting that M-CSF, GM-CSF and FL are involved in cell proliferation stimulated by anti-4-1BBL. Further analysis of the DCs{alpha}-4-1BBL showed increased secretion of Th1-type cytokines IL-12 and IFN-{gamma} and decreased secretion of IL-10. DCs{alpha}-4-1BBL induced much stronger proliferative responses in the mixed lymphocyte reaction assay when compared with DCs derived by GM-CSF. Moreover, DCs{alpha}-4-1BBL preferentially induced Th1 responses. We have further demonstrated that anti-4-1BBL antibody stimulated nuclear translocation of NF-{kappa}B from the cytoplasm in monocytes, suggesting that reverse signaling by 4-1BBL is likely responsible for mediating DC differentiation. Collectively, we have found that reverse signaling of 4-1BBL promotes the differentiation of potent Th1-inducing DCs from human monocytes.

Keywords: 4-1BBL, co-stimulatory molecule, dendritic cells, monocytes, reverse signaling


* These authors have contributed equally to this work.

Transmitting editor: R. A. Flavell

Received 29 January 2009, accepted 19 July 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.